Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Spectranetics Gets FDA Approval for Final Phase of LACI Trial
Feb 2001
COLORADO SPRINGS, Colo., Feb. 8 -- The Spectranetics Corp. has received approval from the US Food and Drug Administration to begin the second phase of its Laser Angioplasty for Critical Limb Ischemia (LACI) trial, which is intended to demonstrate the safety and effectiveness of laser angioplasty technology to treat blockages in arteries of the leg, primarily at or below the knee. The company will begin the phase 2 trial immediately and enrollment is expected to take 12-15 months to complete.
We're excited to begin Phase 2 of the LACI trial because results from Phase 1 were so promising, said John R. Laird, the LACI principal investigator at Washington Hospital Center in Washington, D.C. Although our primary endpoint for Phase 1 was wound healing at three months, the compelling observation when reviewing the data was that the vast majority of the patients in the study still had their limbs six months later. Without laser angioplasty, we would have expected significantly more major amputations among the group. The LACI investigators believe laser angioplasty will bring new hope to patients who have very few options left.

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.